PrEP

News

Four women, seen from the back, hold each other behind each's back

Campaign seeks to plug HIV care gap for UK women

ViiV's campaign wants communication between women and healthcare workers about HIV to move beyond harmful stereotypes and 'risk' labels.

Patients

Gilead's HIV success and controversy: Expanding access amid ...

Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly effective medicine.

News

Gilead strikes deal to expand HIV drug access in 120 countri...

Gilead Sciences has taken a major step towards increasing global access to HIV prevention with the signing of royalty-free

News

AstraZeneca files rival to Pemgarda for COVID PrEP

AstraZeneca may have exited the COVID-19 vaccine market, but it is still hoping to protect vulnerable patients with its antibody sipavibart for pre-exposure prophylaxis (PrEP).

News

Gilead’s twice-yearly HIV PrEP 100% effective, says study

Gilead Sciences’ already dominant position in HIV pre-exposure prophylaxis (PrEP) has been consolidated by a new study showing that its twice-yearly injectable drug was 100% effective in pr

News